Triage Considerations for Patients Referred for Structural Heart Disease Intervention During the COVID-19 Pandemic: An ACC/SCAI Position Statement.


Journal

JACC. Cardiovascular interventions
ISSN: 1876-7605
Titre abrégé: JACC Cardiovasc Interv
Pays: United States
ID NLM: 101467004

Informations de publication

Date de publication:
22 06 2020
Historique:
received: 30 03 2020
revised: 02 04 2020
accepted: 02 04 2020
pubmed: 7 4 2020
medline: 3 7 2020
entrez: 7 4 2020
Statut: ppublish

Résumé

The coronavirus disease-2019 (COVID-19) pandemic has strained health care resources around the world, causing many institutions to curtail or stop elective procedures. This has resulted in an inability to care for patients with valvular and structural heart disease in a timely fashion, potentially placing these patients at increased risk for adverse cardiovascular complications, including CHF and death. The effective triage of these patients has become challenging in the current environment as clinicians have had to weigh the risk of bringing susceptible patients into the hospital environment during the COVID-19 pandemic against the risk of delaying a needed procedure. In this document, the authors suggest guidelines for how to triage patients in need of structural heart disease interventions and provide a framework for how to decide when it may be appropriate to proceed with intervention despite the ongoing pandemic. In particular, the authors address the triage of patients in need of transcatheter aortic valve replacement and percutaneous mitral valve repair. The authors also address procedural issues and considerations for the function of structural heart disease teams during the COVID-19 pandemic.

Identifiants

pubmed: 32250751
pii: S1936-8798(20)30867-0
doi: 10.1016/j.jcin.2020.04.001
pmc: PMC7270905
pii:
doi:

Types de publication

Practice Guideline Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

1484-1488

Commentaires et corrections

Type : CommentIn
Type : CommentIn

Informations de copyright

Copyright © 2020 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.

Références

J Am Coll Cardiol. 2018 May 1;71(17):1841-1853
pubmed: 29699609
J Am Heart Assoc. 2017 Jun 27;6(6):
pubmed: 28655733
JACC Cardiovasc Interv. 2013 Aug;6(8):867-75
pubmed: 23871511
Circulation. 2017 Nov 28;136(22):2132-2140
pubmed: 28864443
Circulation. 2018 Jul 31;138(5):483-493
pubmed: 29511000
Circ Cardiovasc Interv. 2020 Mar;13(3):e008425
pubmed: 32138529
J Am Heart Assoc. 2019 Jan 8;8(1):e010407
pubmed: 30612506

Auteurs

Pinak B Shah (PB)

American College of Cardiology Interventional Cardiology Section Leadership Council, Washington, DC; Division of Cardiovascular Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts. Electronic address: pbshah@partners.org.

Frederick G P Welt (FGP)

American College of Cardiology Interventional Cardiology Section Leadership Council, Washington, DC; Cardiovascular Division, University of Utah Health, Salt Lake City, Utah.

Ehtisham Mahmud (E)

Society for Cardiovascular Angiography and Interventions, Washington, DC; Division of Cardiovascular Medicine, University of California-San Diego, San Diego, California.

Alistair Phillips (A)

American College of Cardiology Cardiac Surgery Team and Leadership Council, Washington, DC; The Heart, Vascular, and Thoracic Institute, Cleveland Clinic, Cleveland, Ohio.

Neal S Kleiman (NS)

American College of Cardiology Interventional Cardiology Section Leadership Council, Washington, DC; Cardiovascular Division, Houston Methodist Hospital, Houston, Texas.

Michael N Young (MN)

American College of Cardiology Interventional Cardiology Section Leadership Council, Washington, DC; Cardiovascular Division, Dartmouth-Hitchcock Medical Center, Geisel School of Medicine at Dartmouth, Lebanon, New Hampshire.

Matthew Sherwood (M)

American College of Cardiology Interventional Cardiology Section Leadership Council, Washington, DC; Division of Cardiology, Inova Heart and Vascular Institute, Fairfax, Virginia.

Wayne Batchelor (W)

American College of Cardiology Interventional Cardiology Section Leadership Council, Washington, DC; Division of Cardiology, Inova Heart and Vascular Institute, Fairfax, Virginia.

Dee Dee Wang (DD)

Henry Ford Health System, Center for Structural Heart Disease, Wayne State University School of Medicine, Detroit, Michigan.

Laura Davidson (L)

American College of Cardiology Interventional Cardiology Section Leadership Council, Washington, DC; Bluhm Cardiovascular Institute, Feinberg School of Medicine, Northwestern University, Chicago, Illinois.

Janet Wyman (J)

American College of Cardiology Interventional Cardiology Section Leadership Council, Washington, DC; Henry Ford Health System, Center for Structural Heart Disease, Wayne State University School of Medicine, Detroit, Michigan.

Sabeeda Kadavath (S)

American College of Cardiology Interventional Cardiology Section Leadership Council, Washington, DC; Department of Cardiovascular Medicine, University of Arkansas for Medical Sciences, Little Rock, Arkansas.

Molly Szerlip (M)

Society for Cardiovascular Angiography and Interventions, Washington, DC; Baylor Scott and White, The Heart Hospital Plano, Plano, Texas.

James Hermiller (J)

Society for Cardiovascular Angiography and Interventions, Washington, DC; Ascension Medical Group, Indianapolis, Indiana.

David Fullerton (D)

American College of Cardiology Cardiac Surgery Team and Leadership Council, Washington, DC; Division of Cardiothoracic Surgery, University of Colorado School of Medicine, Denver, Colorado.

Saif Anwaruddin (S)

American College of Cardiology Interventional Cardiology Section Leadership Council, Washington, DC; Cardiovascular Division, The Hospital of the University of Pennsylvania, Perelman School of Medicine, Philadelphia, Pennsylvania.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH